Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

PURPOSE: Levomilnacipran extended-release (ER) is indicated for treatment of major depressive disorder in adults. We evaluated the pharmacokinetic and safety profile of levomilnacipran ER in individuals with impaired renal function. METHODS: A total of 32 individuals participated in four groups (eig...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Laishun, Greenberg, William M, Brand-Schieber, Elimor, Wangsa, Julie, Periclou, Antonia, Ghahramani, Parviz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485797/
https://www.ncbi.nlm.nih.gov/pubmed/26150701
http://dx.doi.org/10.2147/DDDT.S85418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485797/
https://www.ncbi.nlm.nih.gov/pubmed/26150701
http://dx.doi.org/10.2147/DDDT.S85418

Ejemplares similares